NEW YORK – LumaCyte, a research and bioanalytical instrumentation company based in Charlottesville, Virginia, said today that it has received CE marking for Radiance, the company's label-free, single-cell analysis instrument.
The Radiance platform uses laser force cytology technology to measure optical and fluidic forces within a microfluidic channel to identify and measure the intrinsic cellular properties of each cell.
The company said that applications of the platform include analysis of viral infectivity for vaccine development and manufacturing, cancer biology R&D, CAR-T immunotherapy, cell and gene therapy, induced pluripotent stem cells, infectious disease, pre-clinical drug discovery, and quality control and process optimization for biomanufacturing.
The company also noted that it recently doubled its Charlottesville manufacturing and laboratory space.
"Customer demand is driving our need for additional space and resources," Sean Hart, LumaCyte's CEO and CSO, said in a statement, adding that biopharma and contract development and manufacturing organizations are increasingly looking to apply analytical solutions like Radiance into their R&D and biomanufacturing processes.